overall certainty of evidence for treatment in this population is low, and numerous potentially influential individual patient factors need to be weighed when selecting treatment. For adult renal transplant recipients on chronic GC treatment, we conditionally recommend metabolic bone disease expert evaluation for chronic kidney disease-mineral and bone disorder (CKD-MBD). In patients with stage IV and V CKD, renal osteodystrophy, including adynamic bone disease, osteomalacia, osteitis fibrosa